Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
Katie, who works at Milbourn Equine, is now preparing with her horse Templar Justice, or TJ for short, to take part in what is widely acknowledged to be one of the world's most difficult equestrian events.
Last year, she competed at the Burghley Horse Trials and was voted "Amateur Rider of the Year" by Horse and Hound magazine.
Katie says she is determined to build on that success with a strong showing at Badminton: "The Burghley Horse Trials were amazing last year. I was so excited to be there and it went so well. To now be competing at Badminton will be an awesome experience.
"It’s one of only six 'five-star' equestrian events in the world and to compete there really is my dream come true."
The company is now inviting practices to sign up for the free Beta trial and shape the development of the new platform and how video consultations can be integrated into traditional ways of working.
The platform, which can be branded with the practice logo, uses an app which clients download onto their mobile devices and use to book appointments. The system has its own appointment booking system, but also integrates with Vetstoria. When an appointment is booked via video, practitioners see it in their PMS. They then visit their online account, select the relevant appointment and click ‘start video call’. Payment can be collected from the owner prior to the consultation.
Susie Samuel, Managing Director of VetHelpDirect said: "While developing this product, we have been mindful that the use of telemedicine in our industry has been hugely controversial. We believe that inviting local vets to trial and refine this technology, using their team to work with their own clients removes many of the risks and dangers otherwise inherent in the proposition."
I agree wholeheartedly. The controversy over telemedicine has been about the idea of allowing the prescription of drugs to animals that have not been seen in person. Using a service like this (or the one launched by the Virtual Vet Group last year) to offer video consultations to patients that are already under your care strikes me as an altogether different kettle of fish. I think it will help improve engagement with existing clients, by reducing unnecessary trips to the practice for follow-up or post-operative consultations, saving time, money and the planet.
Susie added: "In our fast-moving world pet owners are increasingly reliant on technology and expect to be able to access services easily. The results of our recent VetHelpDirect research of 419 owners showed 38% of survey respondents said they would like to have the option of a video consultation if it was offered by their own vet. If we are to keep up with this demand, we need to embrace new ways of working."
VetHelpDirect says that whilst it believes that the growth in the use of this technology will change the way veterinary medicine is practiced, video consultations will always work alongside in-person consultations, as just one tool in an overall strategy of care, and certainly will not replace face to face diagnosis.
Let's hope so.
Susie added: "What is clear from our research is that whilst clients would like to be able to have video consultations with a vet their strong preference is for this to be with their own vet; whilst 38% of people would use video consultations with their own vet this falls to only 7% if it is provided by a vet not known to them.
"Of course, telemedicine is by no means the answer in every case, what the new service does offer is flexibility for practitioners and the ability to work in new ways that will benefit the animals and owners. For example, giving free telephone advice has become common place in many practices but is very hard to monetise. Video consultations provide a commercial solution to this problem.”
For more information, or to join the trial, contact Susie Samuel susie@vethelpdirect.com
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
The Kennel Club is calling on the profession to support Get Fit With Fido, its new campaign to help tackle the growing dog obesity crisis by educating owners about the range of different ways to get fit with their dogs..
In addition to the education campaign, Get Fit With Fido also includes a challenge that rewards the dog and dog owner who jointly lose the most weight, and the dog owner and dog who individually lose the most weight, as a result of exercising together. Prizes include a one night stay at the dog friendly, 4* boutique townhouse hotel Flemings Mayfair; a luxury dog bed from Charley Chau and Champagne Afternoon Tea for Two at the Milestone Hotel.
All dog owners who enter Get Fit With Fido, will receive a 20% discount on Crufts and Discover Dogs tickets; as well as advice, tips and tools for owners.
Veterinary practices are being asked to support the campaign by requesting free flyers and posters from the Kennel Club and then displaying them at reception, or in the waiting room.Caroline Kisko, Kennel Club Secretary, said: "Reports indicate that between 30 and 60% of all dogs are overweight so it is more important than ever we keep our dogs happy and healthy. One of the most serious findings in obesity studies that have proven to be related to being overweight in both humans and dogs is a reduced lifespan. An overweight dog is more likely to die younger than a dog of normal weight.
"The findings are shocking and we are trying to educate as many dog owners as possible and call on vets to spread the message of keeping your dog fit and healthy."
To get involved in Get Fit With Fido and receive free flyers and posters, contact the Kennel Club press office at gfwf@thekennelclub.org.uk
For more information, visit www.thekennelclub.org.uk/getfitwithfido
There are 10 candidates standing in this year’s election, including four existing Council members eligible for re-election and six candidates not currently on Council. They are:
Mr David Catlow MRCVS
John C Davies MRCVS
Dr Mandisa Greene MRCVS
Miss Karlien Heyrman MRCVS
Professor John Innes FRCVS
Dr "Not Again" Thomas Lonsdale MRCVS
Dr Susan Paterson FRCVS
Mr Matthew Plumtree MRCVS
Mr Iain Richards MRCVS
Colonel Neil Smith FRCVS
The biographies and statements for each candidate can be found at www.rcvs.org.uk/vetvote18.
At the time of writing, the College is still waiting for the Legislative Reform Order (LRO) concerning its governance arrangements, including a reduction in the size of Council, to be approved.
Under current arrangements six candidates will be elected to RCVS Council – however, if the LRO completes the legislative process and is passed by both Houses of Parliament, then only the three candidates with the most votes will take up their places on Council.
Ballot papers and candidates’ details are due to be posted to all veterinary surgeons eligible to vote during the week commencing 12 March, and all votes must be cast, either online or by post, by 5pm on Friday 27 April 2018.
Once again this year the College is inviting veterinary surgeons to email a question for the candidates to vetvote18@rcvs.org.uk or tweet it using the hashtag #vetvote18 by midday on Monday 26 February.
Each candidate will then be asked to answer two questions from all those received, and produce a video recording of their answers. Recordings will be published on the RCVS website and YouTube channel (www.youtube.com/rcvsvideos) on the week the election commences.
Eleanor Ferguson, RCVS Registrar, said:"After last year’s record turnout in the RCVS Council elections we are continuing to work with Electoral Reform Services (ERS) to make it easier for members to vote for their preferred candidates.
"While the traditional paper ballot papers and booklets will be posted as usual, ERS will once again send personalised emails linking members to their unique secure voting website and then send regular reminders to those who haven’t yet had the chance have their say."
The charity says that it had already been suffering a period of 'dire financial constraints' and the economic effects of coronavirus are now having a direct effect on funding.
The charity's Trustees and Executive Committee is still trying to find emergency funding to try and save the organisation, failing which it will close on the 31st March.
A survey carried out by Rachel Crowe BSc PhD in association with Virbac Animal Health and VetSurgeon.org has revealed what veterinary surgeons in the UK expect from pharmaceutical companies and other suppliers.
The survey considers a number of different aspects of the relationship between vets and pharmaceutical companies, from the importance of quality products through to the question of what vets expect from company representatives.
Chris Liggett, Marketing Director at Virbac UK said: "The findings of this survey offer a fascinating insight into the relationship between veterinary practices and their suppliers. In some ways they confirm what we should all already know - that the quality of a company's product range is paramount and that representatives play a key role as ambassadors for our businesses - but the growing importance to vet practices of working with drug companies that provide a complete package of products and services is worthy of note."
The full report is available to download here.
Jon Pycock, President of BEVA said: "A significant number of BEVA members have young children and we want to make it as easy as possible for them to enjoy Congress without having to worry about making separate plans for childcare at home. We have already had a great response to the idea and it’s looking like the crèche is going to be very popular."
The theme of this year's Congress is helping horse vets celebrate the benefits and pleasures of their job.
In addition to the social and scientific programme at Congress, there will be special sessions on reproduction, non-clinical aspects of being a vet, succession planning, a moral maze debate on specials manufacturing and role play demonstrations on how to manage difficult situations in practice.
Dr Juan Samper, Associate Dean for students and instruction at the University of Florida College of Veterinary Medicine will be giving the plenary lecture on the challenges and opportunities in equine practice.
There will also be specific lecture streams for veterinary nurses, equine dental technicians and farriers.
For more information on the BEVA Congress crèche or to reserve your child's place, contact Jocelyn@beva.org.uk or call 01638 723558. BEVA says places are limited so early booking is advised.
The BEVA Congress programme can be viewed at www.bevacongress.org.
At the hearing, the Disciplinary Committee considered whether she had accepted the findings of the Committee at the original inquiry hearing, the seriousness of those findings, whether she had demonstrated insight into her past conduct, and the protection of the public and the public interest.
In her restoration application, Dr Burrows included continuing professional development (CPD) certificates for the courses she had completed since her removal from the Register, letters/informal witness statements from the veterinary surgeons and nurses she had worked who had expressed a willingness to employ her again, together with character references and reflection statements.
She also made a detailed opening statement in support of her application, in which she said that the period since her name was removed from the Register was extremely difficult and also that she now unconditionally accepted all the Committee’s original findings in May 2021, some of which she had previously denied and had failed to acknowledge.
Dr Burrows went on to state that she only had herself to blame for her actions and that she now understood and accepted that the original sanction of removal from the register had needed to be severe given the serious breach of trust to the public, to the veterinary profession and the insurance industry that was a direct consequence of her dishonest actions.
Since removal from the Register, Dr Burrows had taken on the role of receptionist in a Vets4Pets practice in Cardiff, which required her to deal directly with the public and their insurance requests and entitlements.
She stated that as a result of her involvement over the past 18 months in processing insurance claims, she acknowledges the “delicate” relationship between veterinary surgeons, clients and insurers.
Additionally, working as a receptionist, had allowed her to recognise the need for contemporaneous and clear clinical notes.
She also highlighted her CPD, which was relevant to insurance, as well as the fact she’d undertaken a professional ethics course to assist her rehabilitation, reflection, and insight.
In support of Dr Burrows’ restoration to the Register, the Committee took into account three witness accounts from people who work at the Vets4Pets branch where Dr Burrows works as a receptionist.
All witnesses gave positive reflections on Dr Burrows’ character and assured the Committee that they would provide the correct level of support to allow her to return to work safely and that they would have all the necessary safeguarding measures in place to ensure that the public’s and the profession’s interest is always at the forefront.
Judith Way, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee was impressed by the fact that busy professionals chose to give up their time to provide witness statements and give evidence in support of Dr Burrows’ application.
"All witnesses were clearly supportive of Dr Burrows’ request for restoration to the Register.
“The Committee found Dr Burrows to show remorse and she does now accept the findings of dishonesty that were made against her in the original enquiry hearing and stated that her conduct was dishonest.
"In the Committee’s view, the evidence given by Dr Burrows on affirmation was very believable and she now accepts her dishonesty together with the gravity of her dishonesty.
“The Committee also formed the view that the steps she has taken to address her dishonesty serve to confirm that she is passionate about the prospect that she be allowed to return to practise.
"The Committee was impressed by Dr Burrows and the evidence given and is now satisfied that she will ensure the highest standards of probity and honesty in the future.
“Having taken all evidence into account, the Committee is satisfied that the future welfare of animals under Dr Burrows’ responsibility will be properly protected, and that her future dealings with insurers will be honest in all respects and that the interests of the public will be met.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
The Disciplinary Committee (DC) of the Royal College of Veterinary Surgeons has suspended a veterinary surgeon for a period of six months for issuing two false horse passports, having found him to have been “consciously dishonest”.
At a hearing which concluded on 15 July, Andrew Dominic Illing, Director of the Chapelfield Veterinary Partnership, Norwich, admitted charges of backdating the passports of two different horses on 1 May 2008, to indicate that they had been vaccinated on 24 April 2008 against equine influenza and equine influenza and tetanus, when he knew that the vaccinations had not been carried out on that date.
The Committee heard that, whilst on a routine visit to a local livery yard on 30 April 2008, a junior veterinary surgeon at the practice, Ms Charlotte Alice Mayers, had been pressured to backdate the equine passports of two horses, owned by Mrs Scriven and Mrs Kippen respectively, because their booster vaccinations had been carried out beyond the 12-month window prescribed by the Horse Racing Authority. Ms Mayers had declined to do so and had brought the passports back to the practice to seek the advice of its Director, Mr Illing.
Ms Mayers explained to Mr Illing, both in a note and in discussion with him, that the boosters had been administered outwith the prescribed period and that she had told the owners that she was not willing to backdate the passports, one of which she had already signed. The DC heard that Mr Illing had told Ms Mayers “not to worry about it” and that he would deal with the situation. It did not surface until the livery yard manager later made a complaint, that Mr Illing had in fact signed the second passport and backdated both to 24 April.
In mitigation, Mr Illing said that he had been under considerable stress at the time, as he had been dealing with a protracted and difficult disciplinary meeting concerning a senior veterinary colleague. As a consequence of this, the Committee heard from Mr Illing’s practice partner that Mr Illing was required to take on more work than he was already performing, which was already 10-15% more than the other three vets in the practice. In addition, Mr Illing had been in a degree of pain at the time, following a knee injury. The Committee also heard evidence from a veterinary surgeon who testified to Mr Illing’s good character; and received many written testimonials.
In reaching its decision, the Committee held the view that: “the public must be able to trust certificates which are signed by members of this profession. If the public cannot trust the authenticity of such certificates, the Committee considers that public confidence in the profession would be undermined, and undermined in a very significant way.” It also cited the obligations of the RCVS Guide to Professional Conduct in terms of the integrity of veterinary certification, and the ‘12 Principles of Certification’, as agreed by the RCVS, the British Veterinary Association and the Department of Environment, Food and Rural Affairs.
The Committee considered many factors when making its final decision. It did not accept that stress overbore Mr Illing’s normal way of dealing with certification, particularly where he had had a period of overnight reflection before taking the action that he did. However, it felt that the most troubling feature in his decision to backdate the certificates was that, in advising Ms Mayers on a difficult ethical issue, Mr Illing had “set a disgraceful example and wholly failed to provide her with the support to which she was entitled”. Furthermore, in backdating a certificate that Ms Mayers had already signed, he was putting her integrity at risk.
Alison Bruce, chairing the Committee, commented: “It is only by upholding the importance of each and every certificate issued by a member of the veterinary profession that public confidence in such certificates can be maintained.” She went on to say: “Without significant mitigating circumstances, false certification will result in removal from the Register. In Mr Illing’s case, having regard to all the evidence, both the oral and written testimonials, and taking into account all the aggravating and mitigating circumstances detailed above, the Committee has decided to suspend Mr Illing’s name from the Register for a period of six months.”
The charity says that one of the biggest issues it faces with guinea pigs is multi-animal households where breeding has become out of control.
Dr Jane Tyson, the RSPCA’s rodent expert, said: "We would always advise owners to have their male guinea pigs neutered before introducing them to a female. We also find that they can sometimes be mis-sexed by the seller or previous owner which leads to accidental breeding so it’s also important to make sure that guinea pigs see a vet regularly who would be able to spot if they have been identified incorrectly.
“Many of the guinea pigs that come into our care have come from a multi-animal home where there have been large numbers of guinea pigs living in often cramped, dirty and unsuitable conditions. This also means that they may have experienced very little handling and are wary and fearful of human hands and need their confidence building up in RSPCA care.
“This is why, this Guinea Pig Appreciation Day, we wanted to encourage people to neuter their guinea pigs and help tackle the problem of overbreeding.”
Invicta Animal Health has announced the launch of Ocuvance, a nutritional supplement to support ocular health in dogs and cats.
The company says Ocuvance is formulated to provide an antioxidant complex supporting and maintaining the health of eyes. The tablets contain lutein, a xanthophyll pigment found within the eye. They also contain anthocyanosides derived from bilberry extract to support rhodopsin production. The formulation also contains vitamins C and E, zinc and selenium.
Ocuvance is presented in packs of 30 scored tablets; sufficient for a one month supply for the average sized dog.
Rob Watkins, Managing Director of Invicta, said: "We are delighted to make Ocuvance available to veterinary surgeons in the UK. A recent veterinary study1 has shown there can be significant ophthalmic benefits of antioxidant supplementation.
We carefully formulated Ocuvance to provide a range of high quality ingredients to maintain normal visual function whilst still being affordable for owners”.
Ocuvance is now available from all veterinary wholesalers.
Reference
The practice says that because thiamine deficiency in cats is generally rare, the number of recent cases seen in the UK has been a cause for concern amongst veterinary surgeons.
Symptoms may include severe weight loss or anorexia, vomiting, impaired vision, dilated pupils, tremors and seizures. Prompt treatment is needed, usually in the form of thiamine injections, an oral supplement and an immediate change of food as a precaution.
Laurent Garosi RCVS & European Veterinary Specialist in Neurology at Davies Veterinary Specialists said: "In 20 years I have only seen a handful of cases. My concern is that there may be many more cats out there in need of a diagnosis which is why we are building awareness and supporting our referring vets in the diagnosis of this condition."
To that end, Laurent posted on the subject on Facebook, which immediately went viral, with more than 1.1 million people reached and 9000+ shares.
Davies Veterinary Specialists has followed Laurent's post with support and advice for pet owners, explaining the symptoms to look out for and the emergency measures to take. The practice has also sent more detailed information direct to its referring practices:
What are the signs of thiamine deficiency in cats? Initially most cats will show anorexia and some degree of vomiting preceding neurological signs which include fairly rapid onset of impaired vision, dilated pupils, ataxia, vestibular signs, tremors and seizures.
How do you diagnose thiamine deficiency? It is based on a combination of factors: clinical presentation, MRI findings, which are fairly typical (although not pathognomonic) and response to thiamine supplementation. Absolute confirmation is technically difficult and not widely available: direct measurement of thiamine in the blood may not reflect deficiency, as this is not a good reflection of tissue concentration of Thiamine. Indirect methods are functional tests looking at effects of thiamine or lack of it: demonstration of reduced transketolase activity in red blood cells which is not readily available for most veterinary practices, or other indirect methods such measuring abnormal metabolites such as organic acids in the urine.
What are the causes of thiamine deficiency in dogs and cats? There are three main causes: 1) inability to absorb thiamine due to gastro-intestinal disease, 2) inability to process thiamine due to liver disease and 3) decreased level of thiamine in food. The latter can be caused by the heating process used for food preparation (thiamine is destroyed by heat), addition of sulphur dioxide or sulphite preservatives to meat which inactivate thiamine and feeding food rich in thiaminase activity such as some raw fish. Therefore all-raw fish diet in cats can be a cause of thiamine deficiency.
What to do if you suspect you have a cat with thiamine deficiency and whose diet consists of a product being recalled? Unless the cat is showing neurological signs, the first step is to stop the diet and switch to another diet not listed in the recall. Thiamine supplementation (intramuscular injection) is advised in the first instance in a case with compatible neurological signs. Other causes for the neurological signs must be considered in the case of failing to respond to Thiamine injections within 24-48 hours.
DVS says it is working closely with their referring vets to raise awareness and diagnose any affected animals.
For more information, visit: www.vetspecialists.co.uk and www.facebook.com/DVSvets/
What is 'quality improvement', you ask? Good question. Sure, it's an improvement in, er, quality. But of what?
'Quality improvement' is a term adopted from the human healthcare sector, variously defined as anything which makes: "healthcare safer, effective, patient-centred, timely, efficient and equitable (NHS)", or "the combined and unceasing efforts of everyone—healthcare professionals, patients and their families, researchers, payers, planners and educators—to make the changes that will lead to better patient outcomes (health), better system performance (care) and better professional development (BMJ)."
The RCVS research project, which is being conducted by RAND EUROPE, will assess current perceptions and adoption of quality improvement in the veterinary profession.
Specifically, it'll look at the drivers, barriers and expectations associated with QI, with the ultimate goal of strengthening the support provided to the profession.
Chris Gush, Executive Director of RCVS Knowledge, said: "We are delighted to be launching this research project with RAND Europe.
"We know that many of our colleagues across the profession have embedded quality improvement into their practice to great benefit, while we are also aware that it can be a challenge to do so all of the time.
"This research will provide an unprecedented body of evidence on the experiences and perceptions of QI, which will be critical to how we work to support the sector in this area going forward."
Integral to the research is a survey which all members of the profession are invited to take part in, here: bit.ly/QIvetsurvey.
The survey will be live for six weeks, closing early April. It takes around ten minutes to complete, with a prize of one £150 Amazon voucher on offer. Responses will be anonymised.
You can read more about Quality Improvement on the RCVS Knowledge website, here: https://knowledge.rcvs.org.uk/quality-improvement/
The committee heard five charges against Dr Davies at a resumed hearing of an inquiry which was originally adjourned in January and then July 2018. The decision was made, at both the 2018 hearings, to postpone the final decision on the sanction.
The first two charges against Dr Davies related to convictions for drink driving in March 2014 and October 2015 for which she received driving bans of 17 and 45 months.
The third charge related to her breaching a number of undertakings she had entered into as part of the College’s Health Protocol, including her consuming alcohol on four occasions between May 2015 and January 2016 and missing a pre-arranged appointment with a consultant psychiatrist appointed.
The fourth and fifth charges related to being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016 which was also in breach of her undertakings under the Health Protocol.
At Dr Davies' first Disciplinary Committee hearing in January 2018, she admitted all five charges against her and also accepted that her conduct was disgraceful conduct in a professional respect.
The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At the conclusion of its hearing on 23 January 2018 the Committee decided to postpone its decision regarding sanction for six months on the basis of Dr Davies’ entering into undertakings, including not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement and to undergo blood and hair tests for alcohol consumption every two months.
At the resumed hearing on 30 July 2018, Dr Davies’ Counsel submitted on her behalf that she wished to return to practise and the Committee reviewed evidence that she provided to demonstrate she had complied with her undertakings.
However, the Committee retained concerns about Dr Davies' return to practise and therefore required her to identify a veterinary surgeon who would agree to act as her mentor, noting that the mentor would have to be acceptable to the College as someone suitable to act in that capacity.
The Committee also required the continuation of the requirements for abstinence from alcohol and the programme of blood and hair testing.
A further requirement of the Committee was that Dr Davies should make a disclosure to any new employer of her appearances before the Committee in January 2018 and in July 2018 and of the decisions it made.
The final requirement of the Committee was that the respondent should not accept a ‘sole charge position’ at any time during her employment during this next period of postponement of sanction. The Committee then directed that the hearing be postponed for a further 12 months.
The Disciplinary Committee resumed its inquiry on 7th August 2019, when Dr Davies submitted documentary proof and medical records to demonstrate she had complied with all her undertakings given at the last hearing. The Committee also heard from Dr Davies’ appointed veterinary mentor who provided a statement that concluded that she no longer needed monitoring or supervision.
The Committee then considered what sanction to impose on Dr Davies.
Ian Green, chairing the Committee and speaking on its behalf, said: "The view of the Committee is that the respondent has to date overcome her addiction to alcohol and, given that her competence as a practising veterinary surgeon is not disputed, that she should therefore be permitted to return to her chosen profession. However, in the judgment of this Committee the seriousness of the offences to which the Respondent has pleaded guilty means that a sanction of “No Further Action” cannot be justified."
The Committee therefore decided that the most proportionate sanction was for Dr Davies to be reprimanded as to the conduct she admitted at previous hearings and that she be warned as to her future conduct.
Ian added: "The respondent must understand that she has been given an opportunity to prove that, for the remainder of her time in practice, she can meet the high standards expected of all registered veterinary surgeons from both other practitioners and from members of the public who entrust the care and treatment of their animals to members of this profession."
The NOAH Code of Practice Committee, chaired by Mr Guy Tritton, has found Dechra Veterinary Products in breach of three items of the NOAH Code, following a complaint.
The complaint related to an advertisement and detailer promoting Felimazole with the wording "Are you taking a heavy-handed approach to hyperthyroidism?" and "with Felimazole, you don't have to!"
The Committee took the view that by implication this referred to Vidalta because Vidalta is the only other licensed oral treatment on the market for hyperthyroidism.
As a result, the Committee found both promotions in breach of Clause 4.3 because of the implication that Vidalta is less safe than Felimazole.
The Committee did not consider the promotions disparaged the manufacturer as there is no evidence to show it is unsafe.
The Committee also found that the table in the detailer (page 4) suggesting that one dosage of 5 mg per day of Felimazole has the same efficacy as two doses of 2.5 mg, (which is contrary to the dosing statement within the SPC: "If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime.") was misleading, contrary to Clause 4.3 of the Code.
Full details of the Committee's rulings are on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortly.
Barclaycard has launched Paywag, a new NFC payment system for dogs.
Installed in a specially designed dog collar, the new system allows dogs to make payments up to £5.00 in value in selected pet stores and veterinary practices.
Zoetis says Lokivetmab targets and neutralizes canine interleukin-31 (IL-31), a cytokine associated with atopic dermatitis which sends the itch signal to the brain.
The company has submitted an application for marketing authorisation of the product, which is conditionally licensed in the US and Canada under the name Canine Atopic Dermatitis Immunotherapeutic, in the European Union.
The new data was presented at the 8th World Congress of Veterinary Dermatology (WCVD).
Supporting the efficacy of Lokivetmab in canine AD, Zoetis presented the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) and other clinical signs associated with atopic dermatitis in dogs.
Veterinary investigators at 15 clinics enrolled 245 client-owned, live-at-home dogs with chronic atopic dermatitis. Lokivetmab or a placebo was administered by subcutaneous injection on day 0, and efficacy was evaluated periodically over 56 days. Dog owners assessed their dog’s pruritus using a visual analog scale (VAS), and investigators assessed the associated skin lesions using Canine Atopic Dermatitis Extent and Severity Index-03 (CADESI-03) scores.
Lokivetmab, injected once subcutaneously, provided dose-dependent improvement in owner-assessed pruritus and clinician-assessed CADESI-03 scores for four to six weeks in dogs with atopic dermatitis.
Zoetis also presented results of a randomized, double-blind, placebo-controlled trial to assess the safety of lokivetmab at the nominal dose tested of 1 mg/kg (range, 1-3.3 mg/kg) in the treatment of canine atopic dermatitis. Veterinary surgeons evaluated 245 client-owned, live-at-home dogs with chronic, naturally-occurring atopic dermatitis. These dogs were randomized at a 2:1 ratio to receive two monthly injections of lokivetmab (162 dogs) or placebo on days 0 and 28.
No immediate hypersensitivity reactions were observed and there were no clinically important differences in clinical pathology results. No apparent adverse drug interactions were reported. Dogs studied were taking a wide variety of medications, which is important because multimodal therapy is commonly prescribed for dogs with atopic dermatitis. Adverse events were reported at a similar frequency between the groups.
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
The anti-emetic, Cerenia (maropitant citrate), has gained licenses for use in puppies from as young as eight weeks of age and in cats from 16 weeks of age in the prevention and treatment of vomiting and reduction of nausea.
Cerenia is an NK-1 receptor antagonist which Pfizer says is effective against both peripheral and central emetic stimuli by acting on the final common pathway for emesis. It is, according to the company, the only NK-1 receptor antagonist licensed for dogs and cats.
Pfizer adds that in addition to the use for general emesis in puppies, Cerenia can also be used for chemotherapy-induced nausea in dogs. Studies in human oncology show that some patients receiving chemotherapy consider nausea to be more distressing than vomiting1. and the use of NK-1 receptor antagonists has shown clear benefits in the prevention of nausea and vomiting in chemotherapy-treated humans2. Cerenia tablets are also for the treatment for motion sickness in dogs aged 16 weeks or older, delivering claimed efficacy up to 93% without sedating the dog.
Kate Grocott, Product Manager for Cerenia, said: "Already successfully used in the treatment and prevention of vomiting and chemotherapy nausea in dogs, the new licence is a positive step forward for the prevention and early treatment of vomiting for puppies as young as eight weeks of age and cats from 16 weeks old. Being able to deploy Cerenia in these cases, will improve quality of life, and increases the likelihood of the animal voluntarily taking food and water thereby assisting in the recovery where there is underlying disease."
The new licence for treatment of cats with Cerenia is associated with the injectable form, while puppies may be treated with either an injection or tablets.
For further information, contact your Pfizer Animal Health account manager or call 0845 300 8034.
References
The Investigating Committee and the Disciplinary Committee are responsible for conducting desk-top investigations and disciplinary hearings in response to complaints, disclosures and notifications that may amount to serious professional misconduct by Registered Farriers.
As the Royal College of Veterinary Surgeons did in 2015, the FRC is splitting off its disciplinary functions from that of its Council, meaning it now needs to recruit new members to perform the role.
More information is available in VetSurgeon Jobs, here.
The survey is open to all veterinary surgeon members and participants will be entered into a free prize draw to win £500 of BEVA CPD vouchers.
As we all know, antibiotic resistance is increasing throughout human and veterinary medicine, and there are few new antibiotics being produced. As BEVA says, it’s therefore imperative for vets to protect the usage of antimicrobials to maintain their effectiveness for the future.
To that end, the purpose of the survey is to help fill in gaps in knowledge about how antimicrobials are being used and also the current landscape of resistant infections encountered in equine practice.
The survey has been designed by Amie Wilson and Dr Gina Pinchbeck at the University of Liverpool and Tim Mair the incoming President of BEVA.
Tim said: "This survey will assess any changes in prescribing of antimicrobials in equine practice since the last survey in 2009. In addition, we will collect data on the current frequency and types of antimicrobial resistant infections seen by clinicians in all areas of equine practice and what infection control and audit practices are currently using to combat this."
The survey results should lead to a greater understanding of the role of antimicrobial treatment in the overall epidemiology of antimicrobial resistance in horses and will help protect antibiotics for the future of equine and human health.
To take part in the survey, visit: https://liverpool.onlinesurveys.ac.uk/beva-questionnaire-2019-final
The results will be announced to coincide with European Antibiotic Awareness Day on 18 November 2019.
If you have any questions about the survey you can contact the researchers direct: Amie Wilson, University of Liverpool A.wilson3@liv.ac.uk; Dr Gina Pinchbeck, University of Liverpool ginap@liv.ac.uk; Tim Mair, British Equine Veterinary Association tim.mair@btinternet.com